SG10201908259WA - Methods of reducing serum levels of fc-containing agents using fcrn antagonsits - Google Patents

Methods of reducing serum levels of fc-containing agents using fcrn antagonsits

Info

Publication number
SG10201908259WA
SG10201908259WA SG10201908259WA SG10201908259WA SG 10201908259W A SG10201908259W A SG 10201908259WA SG 10201908259W A SG10201908259W A SG 10201908259WA SG 10201908259W A SG10201908259W A SG 10201908259WA
Authority
SG
Singapore
Prior art keywords
methods
fcrn
serum levels
containing agents
antagonsits
Prior art date
Application number
Other languages
English (en)
Inventor
Nicolas Ongenae
Torsten Dreier
Peter Ulrichts
Haard Johannes De
Christophe Blanchetot
Original Assignee
Argenx Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba filed Critical Argenx Bvba
Publication of SG10201908259WA publication Critical patent/SG10201908259WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10201908259W 2015-03-09 2016-03-08 Methods of reducing serum levels of fc-containing agents using fcrn antagonsits SG10201908259WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562130076P 2015-03-09 2015-03-09

Publications (1)

Publication Number Publication Date
SG10201908259WA true SG10201908259WA (en) 2019-10-30

Family

ID=55863122

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201908259W SG10201908259WA (en) 2015-03-09 2016-03-08 Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
SG11201707053SA SG11201707053SA (en) 2015-03-09 2016-03-08 Methods of reducing serum levels of fc-containing agents using fcrn antagonsits

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201707053SA SG11201707053SA (en) 2015-03-09 2016-03-08 Methods of reducing serum levels of fc-containing agents using fcrn antagonsits

Country Status (19)

Country Link
US (1) US20160264669A1 (https=)
EP (2) EP3268391B1 (https=)
JP (6) JP2018509413A (https=)
KR (1) KR102720769B1 (https=)
AU (2) AU2016230827B2 (https=)
CA (1) CA2978253A1 (https=)
DK (1) DK3268391T3 (https=)
EA (1) EA038178B1 (https=)
ES (1) ES2882999T3 (https=)
HU (1) HUE056775T2 (https=)
IL (2) IL295425A (https=)
LT (1) LT3268391T (https=)
MX (2) MX386491B (https=)
MY (1) MY188761A (https=)
PL (1) PL3268391T3 (https=)
PT (1) PT3268391T (https=)
SG (2) SG10201908259WA (https=)
WO (1) WO2016142782A1 (https=)
ZA (1) ZA202109042B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201605203UA (en) 2013-12-24 2016-07-28 Argen X N V Fcrn antagonists and methods of use
RS64768B1 (sr) * 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
CA2978253A1 (en) * 2015-03-09 2016-09-15 Argenx Bvba Methods of reducing serum levels of fc-containing agents using fcrn antagonists
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
CN110506056A (zh) 2017-04-21 2019-11-26 斯塔滕生物技术有限公司 抗apoc3抗体和其使用方法
PE20210119A1 (es) 2017-10-31 2021-01-19 Staten Biotechnology B V Anticuerpos anti-apoc3 y metodos de uso de estos
CA3081144A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
WO2020148336A1 (en) * 2019-01-16 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of agents capable of inducing lc3-associated phagocytosis for treating sustained inflammation in patients suffering from chronic liver disease
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
JP7565951B2 (ja) 2019-06-07 2024-10-11 アルジェニクス ビーブイ 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤
WO2021016571A2 (en) * 2019-07-25 2021-01-28 Genzyme Corporation Methods of treating antibody-mediated disorders with fcrn antagonists
JP2023509195A (ja) 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法
CN114341184B (zh) * 2020-02-10 2023-04-04 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
AU2021292200A1 (en) * 2020-06-17 2023-02-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of gene therapy patients
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
JP7755725B2 (ja) * 2021-08-13 2025-10-16 ジャンスー バイオジェッテイ バイオテクノロジー カンパニー リミテッド Ｆｃｒｎを特異的に認識する抗体およびその使用
CN119698429A (zh) 2022-06-15 2025-03-25 阿根思有限公司 Fcrn结合分子及使用方法
CN120344557A (zh) * 2022-11-14 2025-07-18 阿根思有限公司 Fcrn拮抗剂分子及其使用方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6128119A (en) 1997-01-10 2000-10-03 Asahi Kogaku Kogyo Kabushiki Kaisha Beam shaping optical system
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
WO2002040047A2 (en) 2000-11-20 2002-05-23 Canadian Blood Services Method for treating thrombocytopenia with monoclonal ivig
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ATE483472T1 (de) 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
CA2512974A1 (en) 2003-01-13 2004-07-29 Macrogenics, Inc. Soluble fc.gamma.r fusion proteins and methods of use thereof
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
ES2765874T3 (es) 2011-05-25 2020-06-11 Innate Pharma Sa Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
AU2012328819B2 (en) * 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
US20140302028A1 (en) * 2011-11-18 2014-10-09 Merck Sharp & Dohme Corp. Fc containing polypeptides having increased anti-inflammatory properties and increased fcrn binding
JP6285923B2 (ja) 2012-06-22 2018-02-28 トラスティーズ・オブ・ダートマス・カレッジ 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
SG11201605203UA (en) * 2013-12-24 2016-07-28 Argen X N V Fcrn antagonists and methods of use
CA2978253A1 (en) * 2015-03-09 2016-09-15 Argenx Bvba Methods of reducing serum levels of fc-containing agents using fcrn antagonists

Also Published As

Publication number Publication date
KR102720769B1 (ko) 2024-10-22
ZA202109042B (en) 2025-01-29
LT3268391T (lt) 2021-09-10
MY188761A (en) 2021-12-29
JP7391132B2 (ja) 2023-12-04
CA2978253A1 (en) 2016-09-15
IL254403A0 (en) 2017-11-30
JP7823011B2 (ja) 2026-03-03
JP2024037846A (ja) 2024-03-19
PL3268391T3 (pl) 2022-01-03
IL254403B (en) 2022-09-01
IL295425A (en) 2022-10-01
JP2022084868A (ja) 2022-06-07
AU2016230827B2 (en) 2021-10-28
NZ734416A (en) 2024-12-20
BR112017019191A2 (pt) 2018-05-02
HUE056775T2 (hu) 2022-03-28
EP3268391B1 (en) 2021-08-11
JP7050191B2 (ja) 2022-04-07
ES2882999T3 (es) 2021-12-03
AU2021277720A1 (en) 2021-12-23
SG11201707053SA (en) 2017-09-28
MX386491B (es) 2025-03-18
JP2022105084A (ja) 2022-07-12
JP2021073282A (ja) 2021-05-13
AU2016230827A1 (en) 2017-08-24
KR20170131463A (ko) 2017-11-29
EA038178B1 (ru) 2021-07-20
JP7403575B2 (ja) 2023-12-22
JP2018509413A (ja) 2018-04-05
EP4006051A1 (en) 2022-06-01
WO2016142782A1 (en) 2016-09-15
AU2021277720B2 (en) 2025-03-27
MX2017011534A (es) 2018-04-10
JP2026012786A (ja) 2026-01-27
EA201791984A1 (ru) 2017-12-29
US20160264669A1 (en) 2016-09-15
DK3268391T3 (da) 2021-09-13
EP3268391A1 (en) 2018-01-17
PT3268391T (pt) 2021-08-19
MX2021011633A (es) 2021-10-22

Similar Documents

Publication Publication Date Title
ZA202109042B (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonists
ZA202409972B (en) Fcrn antagonists and methods of use
NZ764034A (en) Use of fcrn antagonists for treatment of generalized myasthenia gravis
SG196839A1 (en) Antibodies against fcrn and use thereof
MY187975A (en) Antigen-binding proteins that activate the leptin receptor
GEP20237480B (en) Antibodies against signal-regulatory protein alpha and methods of use
MX2021005193A (es) Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes.
SA518391704B1 (ar) C5 أجسام مضادة لـ وطرق لاستخدامها
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
JOP20190002A1 (ar) أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم
MX384026B (es) Terapeuticos de anticuerpo que se unen a ctla4.
EP3991748A3 (en) Anti-sortilin antibodies and methods of use thereof
EP4371570A3 (en) Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
HK1207655A1 (en) Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
EA201892063A1 (ru) МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn
WO2017006052A3 (fr) UTILISATION DE FRAGMENTS Fc MODIFIÉS EN IMMUNOTHÉRAPIE
EA202091239A1 (ru) Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение
SG10201801219VA (en) Anti-HER2 Antibodies
MX371412B (es) ANTICUERPOS BIESPECÍFICOS QUE SE UNEN ESPECÍFICAMENTE A LOXL2 Y ccl.2, COMPOSICIONES DE LOS MISMOS, Y SU USO EN EL TRATAMIENTO DE ESCLERODERMIA.
SG11202000115SA (en) Novel therapeutic enzyme fusion protein and use thereof
EA201892427A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИ-FcRn АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
FR3016888B1 (fr) Synthetases de la colistine et cluster de genes correspondants
PH12018501674A1 (en) Anti-citrullinated hla polypeptide antibodies and uses thereof
WO2021058795A3 (en) Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof